Inhibitory effects on CD8+ T lymphocytes induced by LEV were demonstrated and related to increased incidence of upper respiratory tract infections in LEV-treated patients (Li et al., 2013). The gene discussed is CD8A; the disease is Recurrent upper respiratory tract infections.